Drug intelligence / Profile preview

Genfaxon

Development stage: Unknown
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

Genfaxon is a β-interferon-1a bioanalog, a protein and cytokine, used in the treatment of multiple sclerosis (MS). It functions by modulating the immune system, leading to a significant reduction in the frequency of disease exacerbations. Administered via subcutaneous injections, Genfaxon has demonstrated efficacy in clinical trials, though its use is associated with a high frequency of side effects that can lead to treatment discontinuation.

Other names: Genfaxon-44Genfaxon44Genfaxon 44

Targets

IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)

Beyond the preview

Go deeper on Genfaxon.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genfaxon.

Explore the full profile